2025
Prediction of antipsychotic medication inception in antipsychotic-naive youth at clinical high risk for psychosis
Mukhtar H, Zhou D, Farina E, Saxena A, Cahill J, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshwan M, Mathalon D, Perkins D, Stone W, Cho Y, Powers A, Walker E, Woods S. Prediction of antipsychotic medication inception in antipsychotic-naive youth at clinical high risk for psychosis. Psychological Medicine 2025, 55: e241. DOI: 10.1017/s0033291725101372.BooksClinical high riskCHR-PLifetime historyAugmentation of antidepressant treatmentComorbid major depressionAP useAntidepressant treatmentPositive symptomsMajor depressionAP medicationNAPLS-2Independent predictorsCHR-P.High riskBaseline clinical variablesPsychosisBaseline predictorsClinical variablesParticipantsBaseline characteristicsUnivariate analysisLogistic regression modelsObservational cohortMultivariate analysisAP initiationDebate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer
Sundaresan V, Leapman M. Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer. Seminars In Radiation Oncology 2025, 35: 385-392. PMID: 40516973, DOI: 10.1016/j.semradonc.2025.05.001.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyRadical prostatectomyProstate cancerDeprivation therapyHigh riskEffect of long-term androgen-deprivation therapyLong-term androgen deprivation therapyAdequate randomized clinical trialsLong-term cancer controlHigh-risk prostate cancerRisk of gastrointestinal toxicityDisease-related survivalProportion of patientsDegrees of metastatic potentialResponse to treatmentRandomized clinical trialsCourse of treatmentSequence of surgeryLocal salvageRadiation therapySecondary malignanciesGastrointestinal toxicityInitial surgeryMultimodal treatmentHealth-related quality of lifeConsensus Guideline for the Management of Peritoneal Mesothelioma
Brown L, Wilkins S, Bansal V, Su D, Gomez-Mayorga J, Turaga K, Gunderson C, Lee B, Nash G, Hays J, Raghav K, Husain A, Kluger M, Zauderer M, Kindler H, Alexander H. Consensus Guideline for the Management of Peritoneal Mesothelioma. Annals Of Surgical Oncology 2025, 1-17. PMID: 40560500, DOI: 10.1245/s10434-025-17358-x.Peer-Reviewed Original ResearchPeritoneal mesotheliomaConsensus guidelinesManagement of peritoneal mesotheliomaAssessment of patient characteristicsHigh-risk patientsClinical trial enrollmentPresence of symptomsDisease histologyIntermediate-riskMultimodal therapyMalignant pathologyClinicopathological featuresBenign neoplasmsSurgical interventionRare incidenceClinical evidencePatient characteristicsPathway blockTrial enrollmentHigh riskMultidisciplinary assessmentTherapy timeLimited evidenceMesotheliomaClinical care308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-308-or.Peer-Reviewed Original ResearchDipeptidyl peptidase-4 inhibitorsIncident cancer riskSodium-glucose cotransporter 2 inhibitorsIncident cancerGLP-1RACancer riskHigher risk of incident cancerType 2 diabetesRisk of incident cancerHigh riskReceptor agonistsMedicare fee-for-serviceFemale breast cancerFee-for-serviceGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsPropensity score inverse probabilityTarget trial emulationModerate CVD riskCox proportional hazards modelsOptumLabs Data WarehousePeptidase-4 inhibitorsIncidence of melanomaAdverse cardiovascular events1170-P: Gender Identity, Racial/Ethnic Identity, and Health Behaviors—Which High Schoolers Are at Highest Risk for Type 2 Diabetes?
SHARER A, BRIMACOMBE M, OYOLA-CARTAGENA K, DOYLE R, FINCK C, OLEZESKI C, SANTOS M. 1170-P: Gender Identity, Racial/Ethnic Identity, and Health Behaviors—Which High Schoolers Are at Highest Risk for Type 2 Diabetes? Diabetes 2025, 74 DOI: 10.2337/db25-1170-p.Peer-Reviewed Original ResearchHealth behaviorsYouth Risk Behavior SurveyType 2 diabetesRisk of obesityRegression modelsBinary logistic regression modelTransgender youthLogistic regression modelsPhysical activityRacial/ethnic groupsDevelopment of type 2 diabetesRisk Behavior SurveyUnique stressorsHealthBehavior SurveyObesityMinority stress theoryHigh riskMinority stressNon-significant relationshipT2DYouthTreatment outcomesRiskGender identitySystematic Review and Meta‐Analysis of Dual‐Layered Stents Versus Single‐Layered Stents for Carotid Artery Stenosis
Mari T, Moeed A, Siddiqui A, Abbasi A, Arif Z, Jannat A, Akman Z, Rossi R, Unnar H, Bhatti H, Batool R, Khan M, Ali M, Batool F, Minahil, Iqbal J, Mena‐Hurtado C, Nanna M. Systematic Review and Meta‐Analysis of Dual‐Layered Stents Versus Single‐Layered Stents for Carotid Artery Stenosis. Catheterization And Cardiovascular Interventions 2025 PMID: 40518749, DOI: 10.1002/ccd.31684.Peer-Reviewed Original ResearchCarotid artery stentingCarotid artery stenosisSingle-layer stentsDual-layer stentsAll-Cause MortalityPost-procedural strokeArtery stenosisRandomized Controlled TrialsStent occlusionHigher risk of peri-procedural strokePostprocedural strokeMeta-analysisRisk of peri-procedural strokeRisk ratioHigh riskCarotid artery stenting proceduresStroke riskPeri-procedural strokeRandom-effects meta-analysisPredictors of strokeTreat carotid artery stenosisLipid-rich carotid plaquesTreatment optionsArtery stentingPrimary outcomeRecommendations for Designing a Digital Health Tool for Blindness Prevention Among High-Risk Diabetic Retinopathy Patients: Qualitative Focus Group Study of Adults With Diabetes
Frimpong A, Granados A, Chang T, Fu J, Moore S, Applebaum S, Adepoju B, Kaur M, Krishnan V, Levi A, McCall T, Nwanyanwu K. Recommendations for Designing a Digital Health Tool for Blindness Prevention Among High-Risk Diabetic Retinopathy Patients: Qualitative Focus Group Study of Adults With Diabetes. JMIR Formative Research 2025, 9: e65893. PMID: 40513002, PMCID: PMC12180678, DOI: 10.2196/65893.Peer-Reviewed Original ResearchThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Mathalon D, Nicholas S, Roach B, Billah T, Lavoie S, Whitford T, Hamilton H, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión R, Damiani S, Dzafic I, Ebdrup B, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin E, Mayol-Troncoso R, Niznikiewicz M, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf D, Rogers J, Salisbury D, Shaik R, Shankman S, Stevens M, Suen Y, Swann N, Tang X, Thompson J, Tso I, Wenzel J, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Castillo-Passi R, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Upthegrove R, Verma S, Wang J, Wolf D, Zhang T, Bouix S, Pasternak O, Cho K, Coleman M, Dwyer D, Nunez A, Tamayo Z, Wood S, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Woods S, Shenton M, Light G. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia 2025, 11: 85. PMID: 40480970, PMCID: PMC12144291, DOI: 10.1038/s41537-025-00622-0.Peer-Reviewed Original ResearchEvent-related oscillationsEEG power spectral densityClinical outcomesMarkers of illness progressionRisks of antipsychotic drugsAuditory steady state responsePredictor of clinical outcomeMismatch negativityVariable clinical outcomesControlled clinical trialsClinical high riskTest-retest reliabilitySecondary outcome measuresEEG-based measuresVisual P300Antipsychotic drugsPaired t-testEEG protocolsClinical trialsEffective medicationsInterim analysisHigh riskPersonalized treatmentTraditional frequency bandsCHR individualsUrine Biomarkers for Diabetic Kidney Disease Progression in Participants of the Chronic Renal Insufficiency Cohort Study.
Schrauben S, Zhang X, Xie D, Coca S, Greenberg J, Ix J, Shlipak M, Hsu C, Taliercio J, Parikh C, Gutierrez O, Sarnak M, Dobre M, Cohen D, Schelling J, Rao P, Unruh M, Ricardo A, Waikar S, Kimmel P, Bonventre J. Urine Biomarkers for Diabetic Kidney Disease Progression in Participants of the Chronic Renal Insufficiency Cohort Study. Clinical Journal Of The American Society Of Nephrology 2025 PMID: 40493410, DOI: 10.2215/cjn.0000000711.Peer-Reviewed Original ResearchAssociated with higher risk of CKD progressionHigher risk of CKD progressionRisk of CKD progressionAssociated with higher riskHigh urine levelsKidney injury molecule-1Monocyte chemoattractant protein-1Associated with lower riskCKD progressionChemoattractant protein-1Urine biomarkersUrine levelsKIM-1/CrMolecule-1Urine kidney injury molecule-1Urine albumin-to-creatinine ratioLow riskHigh riskAlbumin-to-creatinine ratioUrine MCP-1Progression of diabetic kidney diseaseDiabetic kidney disease progressionMedian Follow-UpChronic Renal Insufficiency CohortChronic Renal Insufficiency Cohort StudyAn international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
Spigel D, Westeel V, Anderson I, Greillier L, Guisier F, Bylicki O, Badin F, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Gubens M, Crowley J, von der Leyen H, Woodard G, Kratz J, Jablons D, Mann M. An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay. Journal Of Clinical Oncology 2025, 43: lba8027-lba8027. DOI: 10.1200/jco.2025.43.17_suppl.lba8027.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease free survivalModified intent-to-treatAdjuvant chemotherapyCell lung cancerLung cancerInterim analysisCycles of platinum-based adjuvant chemotherapyNon-squamous non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized trials of adjuvant chemotherapyModified intent-to-treat populationTumor size > 4 cmNon-squamous NSCLC patientsRandomized to adjuvant chemotherapyTime of chemotherapy initiationMedian disease free survivalImproved disease free survivalPlatinum-based adjuvant chemotherapyTrials of adjuvant chemotherapyHigh riskRandomized to observationMedian Follow-UpPrimary lung cancerProspective randomized trialsDigital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Wigman J, Ching A, Chung Y, Eichi H, Lane E, Langholm C, Vaidyam A, Byun A, Haidar A, Hartmann J, Nunez A, Dwyer D, Nasarudin A, Borders O, Scott I, Tamayo Z, Matneja P, Cho K, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Yassin W, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Wolff P, Rowland L, D’Alfonso S, Pasternak O, Bouix S, McGorry P, Kahn R, Kane J, Bearden C, Woods S, Shenton M, Nelson B, Baker J, Torous J. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 83. PMID: 40461469, PMCID: PMC12134270, DOI: 10.1038/s41537-025-00599-w.Peer-Reviewed Original ResearchDigital componentsDigital health technologiesSmartphone-based digital phenotypingNovel digital health technologiesClinical high riskDigital phenotypingDigital dataHealth technologiesPredictive of transition to psychosisReal-life experiencesSchizophrenia ProgramDaily lifeTransition to psychosisPassive dataEpisode of psychosisPsychosis transitionMapping of experiencesTechnologyHigh riskMeta-analytic studiesCollaborative projectDifferentiating Individual Characteristics Associated with Suicidal Ideations, Plans, and Attempts among low-Income Veterans
Tsai J, Liang J, Maroufy V. Differentiating Individual Characteristics Associated with Suicidal Ideations, Plans, and Attempts among low-Income Veterans. Chronic Stress 2025, 9: 24705470251348749. PMID: 40469920, PMCID: PMC12134512, DOI: 10.1177/24705470251348749.Peer-Reviewed Original ResearchLevels of suicidal behaviorSuicidal ideationSuicide attemptsSuicide planSuicidal behaviorMental health functioning scoresLifetime prevalenceLow-income veteransClinical attentionTreatment targetVeteransIdeationNationally Representative SampleRepresentative sampleSuicideVeteran homelessnessBehaviorFunction scoresHomelessnessHigh riskJoint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States.
Chu L, Wang R, Gross C, Wei J, Lu Y, Krumholz H, Ma X, Chen K. Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States. Circulation 2025 PMID: 40458867, DOI: 10.1161/circulationaha.124.073614.Peer-Reviewed Original ResearchIncident acute myocardial infarctionAcute myocardial infarctionIncreased oddsRisk of acute myocardial infarctionHigher risk of acute myocardial infarctionProbability of acute myocardial infarctionOccurrence of acute myocardial infarctionRandom-effects meta-analysisCase-crossover studyMultivariate random-effects meta-analysisExposure to ozoneRegion-specific estimatesMyocardial infarctionStatistical interaction termsAmbient ozone pollutionPrevention strategiesUnited StatesJoint exposureMeta-analysisAdult ageYoung adultsHigh riskAdultsOddsInteraction termsThe Discrepancy Between Estimated GFR Cystatin C and Estimated GFR Creatinine at 3 Months After Hospitalization and Long-Term Adverse Outcomes
Wen Y, Srialluri N, Farrington D, Thiessen-Philbrook H, Menez S, Moledina D, Coca S, Ikizler T, Siew E, Go A, Hsu C, Himmelfarb J, Chinchilli V, Kaufman J, Kimmel P, Garg A, Grams M, Parikh C. The Discrepancy Between Estimated GFR Cystatin C and Estimated GFR Creatinine at 3 Months After Hospitalization and Long-Term Adverse Outcomes. Kidney International Reports 2025, 10: 1896-1906. DOI: 10.1016/j.ekir.2025.04.003.Peer-Reviewed Original ResearchAcute kidney injuryEnd-stage kidney diseaseHeart failure hospitalizationFailure hospitalizationCystatin CHospitalized adultsRisk of heart failure hospitalizationHigher risk of heart failure hospitalizationLong-term adverse outcomesMedian Follow-UpRisk of end-stage kidney diseaseAge of study participantsPrognostic valuePrognostic markerCardiac eventsKidney injuryRisk stratificationFollow-upAdverse outcomesKidney diseaseEGFRcrHospitalized patientsHigh riskSurvival analysisEGFRcysNovel risk score for patients undergoing Impella-assisted high-risk percutaneous coronary intervention
Lemor A, Shah T, Thompson J, Protty M, Mamas M, Kinnaird T, Bharadwaj A, Truesdell A, Schonning M, Zhang Y, Hussain Y, Falah B, Cohen D, Redfors B, Baron S, Witzke C, Dixon S, Basir M, Lansky A, O'Neill W. Novel risk score for patients undergoing Impella-assisted high-risk percutaneous coronary intervention. Cardiovascular Revascularization Medicine 2025 PMID: 40541479, DOI: 10.1016/j.carrev.2025.05.031.Peer-Reviewed Original ResearchNational Cardiovascular Data RegistryHigh-risk percutaneous coronary interventionRisk scoreBedside risk scoreIn-Hospital MortalityPercutaneous coronary interventionC-indexPercutaneous left ventricular assist deviceCoronary interventionLeft ventricular ejection fractionPredictors of in-hospital mortalityVentricular ejection fractionPre-procedural variablesPoor goodness of fitNovel risk scoreIn-hospital eventsAcute myocardial infarctionLeft main diseaseData registryComplex high-riskClinical decisionsEjection fractionMultivariate regressionLeft ventricular assist deviceHigh riskThalamo-cortical structural co-variation networks are related to familial risk for schizophrenia in the context of lower nuclei volume estimates in patients: an ENIGMA study
Lella A, Antonucci L, Passiatore R, Bellantuono L, Selvaggi P, Popolizio T, Di Sciascio G, Saponaro A, Ricci P, Altamura M, Blasi G, Rampino A, Vriend C, Calhoun V, Rootes-Murdy K, Goldman A, Baeza I, Castro-Fornieles J, Sugranyes G, De la Serna E, Pomarol-Clotet E, Fatjó-Vilas M, Salvador R, Karuk A, Fuentes-Claramonte P, Glahn D, Rodrigue A, Blangero J, Wang L, Lee T, Einenkel K, Hamers S, Gruber O, Preda A, Chung Y, Odkhuu S, Vallée C, Dazzan P, Marcelis M, Michielse S, Brosch K, Stein F, Nenadić I, Straube B, Thomas-Odenthal F, Kircher T, Carruthers S, Rossell S, Sumner P, Van Rheenen T, Demro C, Ramsay I, Sponheim S, Lencer R, Meinert S, Hahn T, Dannlowski U, Grotegerd D, Ciccarelli M, Iasevoli F, Pontillo G, Pearlson G, Cobia D, Piras F, Banaj N, Vecchio D, Barendse M, van Haren N, Jo H, Sim K, Quidé Y, Green M, Slate R, Cecere G, Omlor W, Homan S, Homan P, Thomopoulos S, Psychosis A, Turner J, van Erp T, Thompson P, Bertolino A, Pergola G. Thalamo-cortical structural co-variation networks are related to familial risk for schizophrenia in the context of lower nuclei volume estimates in patients: an ENIGMA study. Biological Psychiatry 2025 PMID: 40345610, DOI: 10.1016/j.biopsych.2025.03.027.Peer-Reviewed Original ResearchNeurotypical controlsThalamic alterationsFamilial riskAssociated with familial riskRandom-effects meta-analysesFamilial high riskStructural brain differencesStructural MRI scansENIGMA studyStructural co-variance networkThalamo-corticalHigh riskMRI scansNeurobiological correlatesBrain differencesENIGMA consortiumSchizophreniaFHRThalamusCross-sectional sampleTrait-dependentGenetic riskThalamic subdivisionsMeta-analysesRisk traits511. Associations of Cognitive Functions With EEG-Based Event-Related Potentials and Oscillations in Individuals at Clinical High-Risk for Psychosis: A Canonical Correlation Analysis of NAPLS2 Data
Hua J, Roach B, Hamilton H, Bachman P, Belger A, Carrion R, Duncan E, Johannesen J, Light G, Niznikiewicz M, Shapiro D, Woodberry K, Addington J, Bearden C, Cadenhead K, Cornblatt B, Perkins D, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Mathalon D. 511. Associations of Cognitive Functions With EEG-Based Event-Related Potentials and Oscillations in Individuals at Clinical High-Risk for Psychosis: A Canonical Correlation Analysis of NAPLS2 Data. Biological Psychiatry 2025, 97: s308. DOI: 10.1016/j.biopsych.2025.02.750.Peer-Reviewed Original ResearchMismatch Negativity as a Predictor of Future Outcomes Among Individuals at Clinical High-Risk for Psychosis: Parsing Components of Auditory Predictive Coding in the North American Psychosis-Risk Longitudinal Study (NAPLS3) Sample
Hamilton H, Nicholas S, Hua J, Roach B, Belger A, Carrion R, Duncan E, Johannesen J, Keshavan M, Loo S, Niznikiewicz M, Light G, Billah T, Lavoie S, Whitford T, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Stone W, Tsuang M, Walker E, Woods S, Mathalon D, Schizophrenia A. Mismatch Negativity as a Predictor of Future Outcomes Among Individuals at Clinical High-Risk for Psychosis: Parsing Components of Auditory Predictive Coding in the North American Psychosis-Risk Longitudinal Study (NAPLS3) Sample. Biological Psychiatry 2025, 97: s69. DOI: 10.1016/j.biopsych.2025.02.180.Peer-Reviewed Original Research571. Preliminary Findings on the Association Between Psychotropic Medication and Symptom Profile Changes in Youth at Clinical High Risk for Psychosis
Zhou Q, Ananth A, Yuan E, Ku B, Goldsmith D, Addington J, Bearden C, Cadenhead K, Mukhtar H, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Woods S, Walker E. 571. Preliminary Findings on the Association Between Psychotropic Medication and Symptom Profile Changes in Youth at Clinical High Risk for Psychosis. Biological Psychiatry 2025, 97: s333-s334. DOI: 10.1016/j.biopsych.2025.02.810.Peer-Reviewed Original ResearchCannabis Use in Clinical High-Risk for Psychosis Across Different Legal Environments: Preliminary Findings From the Global Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Study
Penzel N, Kelly S, Seitz-Holland J, Cho K, Corcoran C, Calkins M, Cornblatt B, Jacobs G, Kambeitz J, Lewandowski K, Mittal V, Polosecki P, Shah J, Coleman M, Bearden C, Kane J, Kahn R, McGorry P, Woods S, Shenton M, Nelson B, Pasternak O, Investigators A. Cannabis Use in Clinical High-Risk for Psychosis Across Different Legal Environments: Preliminary Findings From the Global Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Study. Biological Psychiatry 2025, 97: s34-s35. DOI: 10.1016/j.biopsych.2025.02.099.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply